The effects of excipients on transporter mediated absorption.
Traditionally most pharmaceutical excipients used for peroral dosage forms have been considered to be inert, although they have been known to play an important role in governing the release of the active pharmaceutical ingredient (API) required for the desired therapeutic effect. Of considerable interest is the emerging data demonstrating that many of these "inert" excipients may produce subtle changes that could directly or indirectly alter the activity of membrane-spanning proteins such as transporters. In this way, excipients could be altering the overall ADMET properties of an incorporated drug thereby affecting its intended therapeutic efficacy and/or enhancing adverse side effects. Therefore, given this recent evidence, it seems necessary to review what has been reported in the literature on interactions of excipients with human physiological entities, particularly transporters. As of today, safety/toxicity evaluations are typically based on the appearance of gross morphological changes rather than the effects on a cellular level, the ability of excipients in modifying the pharmacological activity of an active drug could lead to toxicity evaluation in routine for each additive used in oral formulations. Further knowledge on this subject will enable formulators to make more rational decisions in dosage form design and will help answer the question of whether certain excipients should be considered active pharmaceutical components of formulations.
Goole
Jonathan
J
Department of Industrial and Physical Pharmacy, College of Pharmacy, Nursing and Health Sciences, Purdue University, West Lafayette, IN, USA. jonathan.goole@ulb.ac.be
Lindley
David J
DJ
Roth
Wyatt
W
Carl
Stephen M
SM
Amighi
Karim
K
Kauffmann
Jean-Michel
JM
Knipp
Gregory T
GT
D018528:ATP-Binding Cassette Transporters / Q000187:drug effects / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D002626:Chemistry, Pharmaceutical; D004339:Drug Compounding; D005079:Excipients / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects*; D007700:Kinetics; D026901:Membrane Transport Proteins / Q000187:drug effects* / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism*; D010599:Pharmacokinetics; D013678:Technology, Pharmaceutical / Q000379:methods
D018528:ATP-Binding Cassette Transporters; D005079:Excipients; D026901:Membrane Transport Proteins; D004364:Pharmaceutical Preparations